Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CD22-CAR T Cell Therapy in Pediatric Acute Lymphoblastic Leukemia
NCT06777979Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2025
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Recommended Phase 2 Dose at 4 weeks and Incidence of adverse events at 4 weeks. Started Apr 2025; status: recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06777979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777979.